Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevasiranib dose comparison in wet AMD
NCT00259753Phase 2Completed
- Sponsor
- OPKO Health
- Start
- Jul 2005
- Primary completion
- Dec 2007
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bevasiranib in exudative macular degeneration (3 arms), sponsored by OPKO Health. Primary endpoint: Change from baseline in macular edema at 12 weeks. Started Jul 2005; status: completed.
02
Drugs
bevasiranib
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT00259753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00259753.